论文部分内容阅读
目的:研究凋亡抑制蛋白Livin在膀胱移行细胞癌(BTCC)组织中的表达情况,探讨Livin蛋白与BTCC发病、演进和复发的关系。方法:应用半定量逆转录-聚合酶链反应(RT-PCR)方法检测30例BTCC组织和10例正常膀胱组织新鲜标本中Livin基因mRNA的表达情况。结果:10例正常膀胱组织Livin基因均无表达,20例膀胱癌组织标本Livin基因为表达阳性(20/30,66.6%),且同时表达Livinα和Livinβ两种亚型。Livin基因是BTCC发生和演进中的早期事件之一,在BTCC早期(Ta+T1)和低分级阶段(G1),Livin有较高的阳性表达率,分别达71.4%和69.2%。Livin基因mRNA表达与BTCC分级和分期无关,但与其是否复发密切相关,复发组Livin阳性率为85.0%,远高于未复发组的16.7%。结论:Livin基因与BTCC的演进和复发有关,可作为BTCC早期诊断和评判术后高复发风险的一项重要指标。
Objective: To investigate the expression of Livin in bladder transitional cell carcinoma (BTCC) and to explore the relationship between Livin protein and the pathogenesis, recurrence and recurrence of BTCC. Methods: The expression of Livin mRNA was detected by semi-quantitative RT-PCR in 30 specimens of BTCC tissues and 10 specimens of normal bladder tissues. Results: Livin gene was not expressed in all 10 cases of normal bladder tissue. The expression of Livin gene in 20 cases of bladder cancer was positive (20/30, 66.6%), and both Livin α and Livin β subtypes were expressed simultaneously. Livin gene is one of the early events in the development and progression of BTCC. Livin has a high positive expression rate of 71.4% and 69.2% in the early stages of BTCC (Ta + T1) and in the low-grade stage (G1), respectively. The expression of Livin mRNA was not related to the grade and stage of BTCC, but it was closely related to its recurrence. The positive rate of Livin in recurrence group was 85.0%, much higher than that in non recurrence group (16.7%). CONCLUSION: Livin gene is associated with the development and recurrence of BTCC, which may serve as an important indicator for the early diagnosis and evaluation of postoperative high recurrence risk of BTCC.